{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T14:23:17Z","timestamp":1793370197868,"version":"4.5.0"},"reference-count":126,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T00:00:00Z","timestamp":1734566400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["AAPS PharmSciTech"],"DOI":"10.1208\/s12249-024-03010-6","type":"journal-article","created":{"date-parts":[[2024,12,19]],"date-time":"2024-12-19T20:15:58Z","timestamp":1734639358000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Gene Therapy: Towards a New Era of Medicine"],"prefix":"10.1208","volume":"26","author":[{"given":"Mokshit","family":"Bhagat","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raj","family":"Kamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jyoti","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kirandeep","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thakur Gurjeet","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rohit","family":"Bhatia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3266-7649","authenticated-orcid":false,"given":"Ankit","family":"Awasthi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,19]]},"reference":[{"issue":"1","key":"3010_CR1","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","volume":"6","author":"JT Bulcha","year":"2021","unstructured":"Bulcha JT, Wang Y, Ma H, Tai PWL, Gao G. Viral vector platforms within the gene therapy landscape. Signal Transduct Target Ther. 2021;6(1):53.","journal-title":"Signal Transduct Target Ther"},{"key":"3010_CR2","doi-asserted-by":"publisher","first-page":"695937","DOI":"10.3389\/fnmol.2021.695937","volume":"14","author":"TL Jensen","year":"2021","unstructured":"Jensen TL, G\u00f8tzsche CR, Woldbye DPD. Current and future prospects for gene therapy for rare genetic diseases affecting the brain and spinal cord. Front Mol Neurosci. 2021;14:695937.","journal-title":"Front Mol Neurosci"},{"key":"3010_CR3","unstructured":"Deoxyribonucleic Acid (DNA) Fact Sheet https:\/\/www.genome.gov\/about-genomics\/fact-sheets\/Deoxyribonucleic-Acid-Fact-Sheet.\u00a0Accessed 10 Jul 2024."},{"issue":"7981","key":"3010_CR4","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1038\/s41586-023-06490-x","volume":"622","author":"P Amaral","year":"2023","unstructured":"Amaral P, Carbonell-Sala S, De La Vega FM, et al. The status of the human gene catalogue. Nature. 2023;622(7981):41\u20137.","journal-title":"Nature"},{"key":"3010_CR5","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C HaldAlbertsen","year":"2022","unstructured":"HaldAlbertsen C, Kulkarni JA, Witzigmann D, Lind M, Petersson K, Simonsen JB. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.","journal-title":"Adv Drug Deliv Rev"},{"key":"3010_CR6","doi-asserted-by":"crossref","unstructured":"Adi-Dako O, Kumadoh D, Pathak YV, Gyamerah NK. Overview of development of gene therapy. InGene Delivery Systems. CRC Press; 2022. pp. 1\u201320.","DOI":"10.1201\/9781003186069-1"},{"key":"3010_CR7","doi-asserted-by":"publisher","first-page":"120375","DOI":"10.1016\/j.lfs.2022.120375","volume":"294","author":"N Sayed","year":"2022","unstructured":"Sayed N, Allawadhi P, Khurana A, et al. Gene therapy: comprehensive overview and therapeutic applications. Life Sci. 2022;294:120375.","journal-title":"Life Sci"},{"key":"3010_CR8","doi-asserted-by":"crossref","unstructured":"Zhang J, Li M, Liu M, Yu Q, Ge D, Zhang J. Metal\u2013organic framework nanomaterials as a medicine for catalytic tumor therapy: Recent Advances. Nanomaterials. 2024;14(9):797.","DOI":"10.3390\/nano14090797"},{"key":"3010_CR9","doi-asserted-by":"crossref","unstructured":"Belete TM. The current status of gene therapy for the treatment of cancer. Biol: Targets Ther. 2021;15(null):67\u201377.","DOI":"10.2147\/BTT.S302095"},{"key":"3010_CR10","first-page":"67","volume":"15","author":"TM Belete","year":"2021","unstructured":"Belete TM. The current status of gene therapy for the treatment of cancer. Biologics. 2021;15:67\u201377.","journal-title":"Biologics"},{"issue":"2","key":"3010_CR11","first-page":"171","volume":"42","author":"RA Rashid","year":"2020","unstructured":"Rashid RA, Ankathil R. Gene therapy: an updated overview on the promising success stories. Malays J Pathol. 2020;42(2):171\u201385.","journal-title":"Malays J Pathol"},{"issue":"2","key":"3010_CR12","doi-asserted-by":"publisher","first-page":"104","DOI":"10.2174\/1566523221666210423084233","volume":"22","author":"C Amador","year":"2022","unstructured":"Amador C, Shah R, Ghiam S, Kramerov AA, Ljubimov AV. Gene therapy in the anterior eye segment. Curr Gene Ther. 2022;22(2):104\u201331.","journal-title":"Curr Gene Ther"},{"key":"3010_CR13","doi-asserted-by":"publisher","first-page":"145246","DOI":"10.1016\/j.gene.2020.145246","volume":"769","author":"SM Alnasser","year":"2021","unstructured":"Alnasser SM. Review on mechanistic strategy of gene therapy in the treatment of disease. Gene. 2021;769:145246.","journal-title":"Gene"},{"key":"3010_CR14","unstructured":"Tiwari S, Menghani E. Mode of viral and non-viral gene transfer: an overview. S. Tiwari and E. Menghani, mode of viral and non-viral gene transfer: an overview. International Journal of Advanced Research in Engineering and Technology. 2020;11(11)."},{"issue":"3","key":"3010_CR15","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1016\/j.archoralbio.2014.11.018","volume":"60","author":"K Gupta","year":"2015","unstructured":"Gupta K, Singh S, Garg KN. Gene therapy in dentistry: tool of genetic engineering. Revisited Arch Oral Biol. 2015;60(3):439\u201346.","journal-title":"Revisited Arch Oral Biol"},{"key":"3010_CR16","doi-asserted-by":"crossref","unstructured":"Dwivedi S, Purohit P, Mittal Y, Gupta G, Goel A, Verma RC, Khattri S, Sharma P, Misra S, Pant KK. Genetic engineering: towards gene therapy and molecular medicine. InOmics Technologies and Bio-Engineering. Academic Press; 2018. pp. 507-32.","DOI":"10.1016\/B978-0-12-804659-3.00022-1"},{"issue":"22","key":"3010_CR17","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1056\/NEJMoa2119662","volume":"386","author":"R Leidner","year":"2022","unstructured":"Leidner R, Sanjuan Silva N, Huang H, et al. Neoantigen T-cell receptor gene therapy in pancreatic cancer. N Engl J Med. 2022;386(22):2112\u20139.","journal-title":"N Engl J Med"},{"issue":"11","key":"3010_CR18","doi-asserted-by":"publisher","first-page":"2719","DOI":"10.1007\/s13346-023-01362-3","volume":"13","author":"DM Dogbey","year":"2023","unstructured":"Dogbey DM, Torres VES, Fajemisin E, et al. Technological advances in the use of viral and non-viral vectors for delivering genetic and non-genetic cargos for cancer therapy. Drug Deliv Transl Res. 2023;13(11):2719\u201338.","journal-title":"Drug Deliv Transl Res"},{"key":"3010_CR19","doi-asserted-by":"publisher","first-page":"2986","DOI":"10.1016\/j.csbj.2022.06.015","volume":"20","author":"X Wu","year":"2022","unstructured":"Wu X, He X, Liu F, et al. Development and clinical translation of ex vivo gene therapy. Comput Struct Biotechnol J. 2022;20:2986\u20133003.","journal-title":"Comput Struct Biotechnol J"},{"issue":"7","key":"3010_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.1111\/exd.14314","volume":"30","author":"V Jayarajan","year":"2021","unstructured":"Jayarajan V, Kounatidou E, Qasim W, Di W-L. Ex vivo gene modification therapy for genetic skin diseases\u2014recent advances in gene modification technologies and delivery. Exp Dermatol. 2021;30(7):887\u201396.","journal-title":"Exp Dermatol"},{"issue":"1","key":"3010_CR21","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s43141-020-00078-y","volume":"18","author":"AM Khalil","year":"2020","unstructured":"Khalil AM. The genome editing revolution: review. J Genet Eng Biotechnol. 2020;18(1):68.","journal-title":"J Genet Eng Biotechnol"},{"issue":"1","key":"3010_CR22","doi-asserted-by":"publisher","first-page":"2001238","DOI":"10.1002\/adhm.202001238","volume":"10","author":"Y Wang","year":"2021","unstructured":"Wang Y, Bruggeman KF, Franks S, et al. Is viral vector gene delivery more effective using biomaterials? Adv Healthcare Mater. 2021;10(1):2001238.","journal-title":"Adv Healthcare Mater"},{"key":"3010_CR23","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1007\/164_2023_696","volume":"284","author":"M Sch\u00e4fer-Korting","year":"2024","unstructured":"Sch\u00e4fer-Korting M. Looking to the future: drug delivery and targeting in the prophylaxis and therapy of severe and chronic diseases. Handb Exp Pharmacol. 2024;284:389\u2013411.","journal-title":"Handb Exp Pharmacol"},{"issue":"1","key":"3010_CR24","doi-asserted-by":"publisher","first-page":"e10258","DOI":"10.1002\/btm2.10258","volume":"7","author":"Z Zhao","year":"2022","unstructured":"Zhao Z, Anselmo AC, Mitragotri S. Viral vector-based gene therapies in the clinic. Bioeng Transl Med. 2022;7(1):e10258.","journal-title":"Bioeng Transl Med"},{"issue":"4","key":"3010_CR25","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1016\/j.ymthe.2023.02.001","volume":"31","author":"L Jiang","year":"2023","unstructured":"Jiang L, Wang D, He Y, Shu Y. Advances in gene therapy hold promise for treating hereditary hearing loss. Mol Ther. 2023;31(4):934\u201350.","journal-title":"Mol Ther"},{"issue":"4","key":"3010_CR26","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1038\/s41576-020-00298-5","volume":"22","author":"G Ferrari","year":"2021","unstructured":"Ferrari G, Thrasher AJ, Aiuti A. Gene therapy using haematopoietic stem and progenitor cells. Nat Rev Genet. 2021;22(4):216\u201334.","journal-title":"Nat Rev Genet"},{"issue":"6","key":"3010_CR27","first-page":"687","volume":"16","author":"X Pan","year":"2021","unstructured":"Pan X, Veroniaina H, Su N, et al. Applications and developments of gene therapy drug delivery systems for genetic diseases. Asian J Pharm Sci. 2021;16(6):687\u2013703.","journal-title":"Asian J Pharm Sci"},{"issue":"4","key":"3010_CR28","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255\u201372.","journal-title":"Nat Rev Genet"},{"key":"3010_CR29","doi-asserted-by":"crossref","unstructured":"Trivedi PD, Byrne BJ, Corti M. Evolving horizons: adenovirus vectors\u2019 timeless influence on cancer, gene therapy and vaccines. Viruses. 2023;15(12):2378.","DOI":"10.3390\/v15122378"},{"issue":"6","key":"3010_CR30","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.3390\/cimb45060307","volume":"45","author":"W Matsunaga","year":"2023","unstructured":"Matsunaga W, Gotoh A. Adenovirus as a vector and oncolytic virus. Curr Issues Mol Biol. 2023;45(6):4826\u201340.","journal-title":"Curr Issues Mol Biol"},{"issue":"3","key":"3010_CR31","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.ymthe.2020.01.001","volume":"28","author":"JL Shirley","year":"2020","unstructured":"Shirley JL, De Jong YP, Terhorst C, Herzog RW. Immune responses to viral gene therapy vectors. Mol Ther. 2020;28(3):709\u201322.","journal-title":"Mol Ther"},{"issue":"1","key":"3010_CR32","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41392-024-01780-w","volume":"9","author":"J-H Wang","year":"2024","unstructured":"Wang J-H, Gessler DJ, Zhan W, Gallagher TL, Gao G. Adeno-associated virus as a delivery vector for gene therapy of human diseases. Signal Transduct Target Ther. 2024;9(1):78.","journal-title":"Signal Transduct Target Ther"},{"key":"3010_CR33","doi-asserted-by":"crossref","unstructured":"Fajardo-Serrano A, Rico AJ, Roda E, Honrubia A, Arrieta S, Ariznabarreta G, Chocarro J, Lorenzo-Ramos E, Pejenaute A, V\u00e1zquez A, Lanciego JL. Adeno-associated viral vectors as versatile tools for Parkinson\u2019s research, both for disease modeling purposes and for therapeutic uses. Int J Mol Sci. 2021;22(12):6389.","DOI":"10.3390\/ijms22126389"},{"key":"3010_CR34","doi-asserted-by":"crossref","unstructured":"Asmamaw Mengstie M. Viral vectors for the in vivo delivery of CRISPR components: advances and challenges.\u00a0Front Bioeng Biotechnol. 2022;10:895713.","DOI":"10.3389\/fbioe.2022.895713"},{"issue":"1","key":"3010_CR35","doi-asserted-by":"publisher","first-page":"2670","DOI":"10.1080\/21505594.2021.1982373","volume":"12","author":"S Zhu","year":"2021","unstructured":"Zhu S, Viejo-Borbolla A. Pathogenesis and virulence of herpes simplex virus. Virulence. 2021;12(1):2670\u2013702.","journal-title":"Virulence"},{"key":"3010_CR36","doi-asserted-by":"crossref","unstructured":"Wilms L, We\u00dfollek K, Peeters TB, Yazdi AS. Infections with Herpes simplex and Varicella zoster virus. JDDG: J Dtsch Dermatol Ges. 2022;20(10):1327\u20131351.","DOI":"10.1111\/ddg.14917"},{"issue":"1","key":"3010_CR37","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/09674845.2020.1803540","volume":"78","author":"M Farsimadan","year":"2021","unstructured":"Farsimadan M, Motamedifar M. The effects of human immunodeficiency virus, human papillomavirus, herpes simplex virus-1 and -2, human herpesvirus-6 and -8, cytomegalovirus, and hepatitis B and C virus on female fertility and pregnancy. Br J Biomed Sci. 2021;78(1):1\u201311.","journal-title":"Br J Biomed Sci"},{"key":"3010_CR38","doi-asserted-by":"crossref","unstructured":"Au HK, Isalan M, Mielcarek M. Gene therapy advances: a meta-analysis of AAV usage in clinical settings.\u00a0Front Med. 2022;8:809118.","DOI":"10.3389\/fmed.2021.809118"},{"key":"3010_CR39","doi-asserted-by":"crossref","unstructured":"Dong W, Kantor B. Lentiviral vectors for delivery of gene-editing systems based on CRISPR\/Cas: current state and perspectives. Viruses. 2021;13(7):1288.","DOI":"10.3390\/v13071288"},{"issue":"4","key":"3010_CR40","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1208\/s12248-021-00608-7","volume":"23","author":"H Zu","year":"2021","unstructured":"Zu H, Gao D. Non-viral vectors in gene therapy: recent development, challenges, and prospects. Aaps j. 2021;23(4):78.","journal-title":"Aaps j"},{"issue":"2","key":"3010_CR41","doi-asserted-by":"publisher","first-page":"e12018","DOI":"10.1002\/bmm2.12018","volume":"1","author":"Z Belhadj","year":"2023","unstructured":"Belhadj Z, Qie Y, Carney RP, Li Y, Nie G. Current advances in non-viral gene delivery systems: liposomes versus extracellular vesicles. BMEMat. 2023;1(2):e12018.","journal-title":"BMEMat"},{"key":"3010_CR42","doi-asserted-by":"crossref","unstructured":"Rakoczy K, Kisielewska M, S\u0119dzik M, Jonderko L, Celi\u0144ska J, Sauer N, Szlasa W, Saczko J, Novickij V, Kulbacka J. Electroporation in clinical applications\u2014The potential of gene electrotransfer and electrochemotherapy. Appl Sci. 2022;12(21):10821.","DOI":"10.3390\/app122110821"},{"key":"3010_CR43","doi-asserted-by":"crossref","unstructured":"Przystupski D, Ussowicz M. Landscape of cellular bioeffects triggered by ultrasound-induced sonoporation. Int J Mol Sci. 2022;23(19):11222.","DOI":"10.3390\/ijms231911222"},{"key":"3010_CR44","doi-asserted-by":"crossref","unstructured":"Fang IJ, Trewyn BG. Application of mesoporous silica nanoparticles in intracellular delivery of molecules and proteins. Methods Enzymol. 2012;508:41\u201359.","DOI":"10.1016\/B978-0-12-391860-4.00003-3"},{"issue":"1","key":"3010_CR45","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li T, Yang Y, Qi H, et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8(1):36.","journal-title":"Signal Transduct Target Ther"},{"key":"3010_CR46","doi-asserted-by":"crossref","unstructured":"Aljabali AaA, El-Tanani M, Tambuwala MM. Principles of CRISPR-Cas9 technology: advancements in genome editing and emerging trends in drug delivery. J Drug Deliv Sci Technol. 2024;92:105338.","DOI":"10.1016\/j.jddst.2024.105338"},{"key":"3010_CR47","first-page":"353","volume":"15","author":"M Asmamaw","year":"2021","unstructured":"Asmamaw M, Zawdie B. Mechanism and applications of CRISPR\/Cas-9-Mediated genome editing. Biologics. 2021;15:353\u201361.","journal-title":"Biologics"},{"key":"3010_CR48","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.jconrel.2022.01.013","volume":"342","author":"EA Taha","year":"2022","unstructured":"Taha EA, Lee J, Hotta A. Delivery of CRISPR-Cas tools for in vivo genome editing therapy: trends and challenges. J Control Release. 2022;342:345\u201361.","journal-title":"J Control Release"},{"key":"3010_CR49","doi-asserted-by":"crossref","unstructured":"Li J, Wu S, Zhang K, Sun X, Lin W, Wang C, Lin S. Clustered regularly interspaced short palindromic repeat\/crispr-associated protein and its utility all at sea: status, challenges, and prospects. Microorganisms. 2024;12(1):118.","DOI":"10.3390\/microorganisms12010118"},{"issue":"5","key":"3010_CR50","doi-asserted-by":"publisher","first-page":"841","DOI":"10.4161\/rna.24203","volume":"10","author":"T Karvelis","year":"2013","unstructured":"Karvelis T, Gasiunas G, Miksys A, Barrangou R, Horvath P, Siksnys V. crRNA and tracrRNA guide Cas9-mediated DNA interference in Streptococcus thermophilus. RNA Biol. 2013;10(5):841\u201351.","journal-title":"RNA Biol"},{"key":"3010_CR51","unstructured":"What is CAR T-cell therapy and how does it work? https:\/\/blog.dana-farber.org\/insight\/2017\/06\/car-t-cell-therapy\/.\u00a0Accessed 10 Jul 2024."},{"issue":"4","key":"3010_CR52","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1080\/15476286.2018.1504546","volume":"16","author":"D Gleditzsch","year":"2019","unstructured":"Gleditzsch D, Pausch P, M\u00fcller-Esparza H, et al. PAM identification by CRISPR-Cas effector complexes: diversified mechanisms and structures. RNA Biol. 2019;16(4):504\u201317.","journal-title":"RNA Biol"},{"issue":"21","key":"3010_CR53","doi-asserted-by":"publisher","first-page":"4160","DOI":"10.1016\/j.molcel.2022.09.032","volume":"82","author":"Y-J Shi","year":"2022","unstructured":"Shi Y-J, Duan M, Ding J-M, et al. DNA topology regulates PAM-Cas9 interaction and DNA unwinding to enable near-PAMless cleavage by thermophilic Cas9. Mol Cell. 2022;82(21):4160-4175.e4166.","journal-title":"Mol Cell"},{"key":"3010_CR54","doi-asserted-by":"publisher","first-page":"1387","DOI":"10.3389\/fonc.2020.01387","volume":"10","author":"F Uddin","year":"2020","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Front Oncol. 2020;10:1387.","journal-title":"Front Oncol"},{"key":"3010_CR55","unstructured":"Chimeric antigen receptor t-cell therapy https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK537294\/.\u00a0Accessed 10 Jul 2024."},{"issue":"11","key":"3010_CR56","doi-asserted-by":"publisher","first-page":"e3550","DOI":"10.1002\/jgm.3550","volume":"25","author":"B Cesur-Erg\u00fcn","year":"2023","unstructured":"Cesur-Erg\u00fcn B, Demir-Dora D. Gene therapy in cancer. J Gene Med. 2023;25(11):e3550.","journal-title":"J Gene Med"},{"key":"3010_CR57","doi-asserted-by":"crossref","unstructured":"Ghahri-Saremi N, Akbari B, Soltantoyeh T, Hadjati J, Ghassemi S, Mirzaei HR. Genetic modification of cytokine signaling to enhance efficacy of CAR T cell therapy in solid tumors. Front. Immunol 2021;12:738456.","DOI":"10.3389\/fimmu.2021.738456"},{"issue":"6","key":"3010_CR58","doi-asserted-by":"publisher","first-page":"2114254","DOI":"10.1080\/21645515.2022.2114254","volume":"18","author":"T AsmamawDejenie","year":"2022","unstructured":"AsmamawDejenie T, Tiruneh GMM, Dessie Terefe G, TadeleAdmasu F, Wale Tesega W, Chekol AE. Current updates on generations, approvals, and clinical trials of CAR T-cell therapy. Hum Vaccin Immunother. 2022;18(6):2114254.","journal-title":"Hum Vaccin Immunother"},{"key":"3010_CR59","doi-asserted-by":"publisher","first-page":"100035","DOI":"10.1016\/j.adcanc.2022.100035","volume":"4","author":"U Ahmad","year":"2022","unstructured":"Ahmad U, Khan Z, Ualiyeva D, et al. Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review. Adv Cancer Biol - Metastasis. 2022;4:100035.","journal-title":"Adv Cancer Biol - Metastasis"},{"key":"3010_CR60","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.procbio.2021.09.003","volume":"111","author":"J-W Hyun","year":"2021","unstructured":"Hyun J-W, Lee K, Kim J-H, et al. Extracellular production of an anti-HER2 single-chain variable antibody fragment in Escherichia coli. Process Biochem. 2021;111:87\u201394.","journal-title":"Process Biochem"},{"key":"3010_CR61","doi-asserted-by":"crossref","unstructured":"Huang Y, Li L, Liu W, Tang T, Chen L. The progress of CAR-T therapy in cancer and beyond. STEMedicine. 2020;1(3):e47.","DOI":"10.37175\/stemedicine.v1i3.47"},{"issue":"2","key":"3010_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/PPO.0000000000000031","volume":"20","author":"CA Ramos","year":"2014","unstructured":"Ramos CA, Savoldo B, Dotti G. CD19-CAR trials. Cancer J. 2014;20(2):112\u20138.","journal-title":"Cancer J"},{"key":"3010_CR63","doi-asserted-by":"crossref","unstructured":"Harrison AJ, Du X, Von Scheidt B, Kershaw MH, Slaney CY. Enhancing co-stimulation of CAR T cells to improve treatment outcomes in solid cancers. Immunother Adv. 2021;1(1):ltab016.","DOI":"10.1093\/immadv\/ltab016"},{"issue":"6","key":"3010_CR64","doi-asserted-by":"publisher","first-page":"2709","DOI":"10.1007\/s00432-022-04547-4","volume":"149","author":"K Drougkas","year":"2023","unstructured":"Drougkas K, Karampinos K, Karavolias I, et al. Comprehensive clinical evaluation of CAR-T cell immunotherapy for solid tumors: a path moving forward or a dead end? J Cancer Res Clin Oncol. 2023;149(6):2709\u201334.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"4","key":"3010_CR65","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","volume":"11","author":"RC Sterner","year":"2021","unstructured":"Sterner RC, Sterner RM. CAR-T cell therapy: current limitations and potential strategies. Blood Cancer J. 2021;11(4):69.","journal-title":"Blood Cancer J"},{"key":"3010_CR66","doi-asserted-by":"publisher","first-page":"903562","DOI":"10.3389\/fimmu.2022.903562","volume":"13","author":"P Kandra","year":"2022","unstructured":"Kandra P, Nandigama R, Eul B, et al. Utility and drawbacks of chimeric antigen receptor T cell (CAR-T) therapy in lung cancer. Front Immunol. 2022;13:903562.","journal-title":"Front Immunol"},{"issue":"2","key":"3010_CR67","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1038\/nrclinonc.2015.152","volume":"13","author":"JB Stone","year":"2016","unstructured":"Stone JB, Deangelis LM. Cancer-treatment-induced neurotoxicity\u2013focus on newer treatments. Nat Rev Clin Oncol. 2016;13(2):92\u2013105.","journal-title":"Nat Rev Clin Oncol"},{"key":"3010_CR68","doi-asserted-by":"crossref","unstructured":"Castaman G, Motlagh H, Pezeshkpoor B. Hemophilia B: diagnosis and management. In: Dorgalaleh A, editor. Congenital bleeding disorders: diagnosis and management. Cham: Springer International Publishing; 2023. 145\u2013171.","DOI":"10.1007\/978-3-031-43156-2_5"},{"issue":"11","key":"3010_CR69","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1056\/NEJMoa2113708","volume":"386","author":"MC Ozelo","year":"2022","unstructured":"Ozelo MC, Mahlangu J, Pasi KJ, et al. Valoctocogene roxaparvovec gene therapy for hemophilia A. N Engl J Med. 2022;386(11):1013\u201325.","journal-title":"N Engl J Med"},{"issue":"6","key":"3010_CR70","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1182\/blood.2019004625","volume":"137","author":"BA Konkle","year":"2021","unstructured":"Konkle BA, Walsh CE, Escobar MA, et al. BAX 335 hemophilia B gene therapy clinical trial results: potential impact of CpG sequences on gene expression. Blood. 2021;137(6):763\u201374.","journal-title":"Blood"},{"key":"3010_CR71","doi-asserted-by":"crossref","unstructured":"Uddin F, Rudin CM, Sen T. CRISPR gene therapy: applications, limitations, and implications for the future. Frontiers in oncology. 2020 Aug 7;10:1387.","DOI":"10.3389\/fonc.2020.01387"},{"issue":"5","key":"3010_CR72","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1016\/j.ymthe.2017.03.033","volume":"25","author":"AW Nienhuis","year":"2017","unstructured":"Nienhuis AW, Nathwani AC, Davidoff AM. Gene therapy for hemophilia. Mol Ther. 2017;25(5):1163\u20137.","journal-title":"Mol Ther"},{"issue":"1","key":"3010_CR73","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/asheducation-2017.1.587","volume":"2017","author":"LA George","year":"2017","unstructured":"George LA. Hemophilia gene therapy comes of age. Hematol Am Soc Hematol Educ Program. 2017;2017(1):587\u201394.","journal-title":"Hematol Am Soc Hematol Educ Program"},{"key":"3010_CR74","doi-asserted-by":"crossref","unstructured":"Braun M, Lange C, Schatz P, Long B, Stanta J, Gorovits B, Tarcsa E, Jawa V, Yang TY, Lembke W, Miller N. Preexisting antibody assays for gene therapy: Considerations on clinical cut-off for patient selection and companion diagnostic requirements. Mol Ther Methods Clin Dev. 2024.","DOI":"10.1016\/j.omtm.2024.101217"},{"issue":"3","key":"3010_CR75","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1056\/NEJMoa2119913","volume":"387","author":"P Chowdary","year":"2022","unstructured":"Chowdary P, Shapiro S, Makris M, et al. Phase 1\u20132 trial of AAVS3 gene therapy in patients with hemophilia B. N Engl J Med. 2022;387(3):237\u201347.","journal-title":"N Engl J Med"},{"issue":"3","key":"3010_CR76","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1208\/s12248-023-00814-5","volume":"25","author":"B Gorovits","year":"2023","unstructured":"Gorovits B, Azadeh M, Buchlis G, et al. Evaluation of cellular immune response to adeno-associated virus-based gene therapy. AAPS J. 2023;25(3):47.","journal-title":"AAPS J"},{"issue":"2","key":"3010_CR77","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymthe.2020.12.007","volume":"29","author":"JR Mendell","year":"2021","unstructured":"Mendell JR, Al-Zaidy SA, Rodino-Klapac LR, et al. Current clinical applications of in vivo gene therapy with AAVs. Mol Ther. 2021;29(2):464\u201388.","journal-title":"Mol Ther"},{"issue":"1","key":"3010_CR78","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1182\/hematology.2019000007","volume":"2019","author":"AC Nathwani","year":"2019","unstructured":"Nathwani AC. Gene therapy for hemophilia. Hematology. 2019;2019(1):1\u20138.","journal-title":"Hematology"},{"key":"3010_CR79","doi-asserted-by":"publisher","first-page":"666666","DOI":"10.3389\/fimmu.2021.666666","volume":"12","author":"HCJ Ertl","year":"2021","unstructured":"Ertl HCJ. T cell-mediated immune responses to AAV and AAV vectors. Front Immunol. 2021;12:666666.","journal-title":"Front Immunol"},{"key":"3010_CR80","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.omtm.2018.07.011","volume":"10","author":"J Sun","year":"2018","unstructured":"Sun J, Shao W, Chen X, et al. An Observational study from long-term AAV Re-administration in two hemophilia dogs. Mol Ther Methods Clin Dev. 2018;10:257\u201367.","journal-title":"Mol Ther Methods Clin Dev"},{"issue":"6","key":"3010_CR81","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1038\/mt.2016.61","volume":"24","author":"K Vercauteren","year":"2016","unstructured":"Vercauteren K, Hoffman BE, Zolotukhin I, et al. Superior in vivo transduction of human hepatocytes using engineered AAV3 capsid. Mol Ther. 2016;24(6):1042\u20139.","journal-title":"Mol Ther"},{"issue":"19\u201320","key":"3010_CR82","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1089\/hum.2020.099","volume":"31","author":"HC Brown","year":"2020","unstructured":"Brown HC, Doering CB, Herzog RW, et al. Development of a clinical candidate AAV3 vector for gene therapy of hemophilia B. Hum Gene Ther. 2020;31(19\u201320):1114\u201323.","journal-title":"Hum Gene Ther"},{"issue":"23","key":"3010_CR83","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1056\/NEJMoa1708538","volume":"377","author":"LA George","year":"2017","unstructured":"George LA, Sullivan SK, Giermasz A, et al. Hemophilia B gene therapy with a high-specific-activity factor IX variant. N Engl J Med. 2017;377(23):2215\u201327.","journal-title":"N Engl J Med"},{"key":"3010_CR84","unstructured":"Narasimhaiah D, Uppin MS, Ranganath P. Genetics and muscle pathology in the diagnosis of muscular dystrophies: an update.\u00a0Indian J Pathol Microbiol. 2022;65(Suppl 1):S259\u201370."},{"issue":"1","key":"3010_CR85","doi-asserted-by":"publisher","first-page":"5820","DOI":"10.1038\/s41467-020-19505-2","volume":"11","author":"K Bulaklak","year":"2020","unstructured":"Bulaklak K, Gersbach CA. The once and future gene therapy. Nat Commun. 2020;11(1):5820.","journal-title":"Nat Commun"},{"key":"3010_CR86","unstructured":"Dosing begins in phase 3 trial of Pfizer\u2019s gene therapy for Duchenne https:\/\/musculardystrophynews.com\/news\/dosing-begins-pfizer-phase-3-trial-pf-06939926-gene-therapy-duchenne\/.\u00a0Accessed 10 Jul 2024."},{"issue":"4","key":"3010_CR87","doi-asserted-by":"publisher","first-page":"489","DOI":"10.3233\/JND-200622","volume":"8","author":"G Cooper-Olson","year":"2021","unstructured":"Cooper-Olson G, Rodino-Klapac LR, Potter RA. Evaluation of the lipid-binding properties of recombinant dystrophin spectrin-like repeat domains R1\u20133. J Neuromuscul Dis. 2021;8(4):489\u201394.","journal-title":"J Neuromuscul Dis"},{"issue":"1","key":"3010_CR88","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/s00277-023-05475-0","volume":"103","author":"RW Merryman","year":"2024","unstructured":"Merryman RW, Redd RA, Freedman AS, et al. A multi-cohort phase 1b trial of rituximab in combination with immunotherapy doublets in relapsed\/refractory follicular lymphoma. Ann Hematol. 2024;103(1):185\u201398.","journal-title":"Ann Hematol"},{"key":"3010_CR89","doi-asserted-by":"publisher","first-page":"950651","DOI":"10.3389\/fphar.2022.950651","volume":"13","author":"J Deng","year":"2022","unstructured":"Deng J, Zhang J, Shi K, Liu Z. Drug development progress in duchenne muscular dystrophy. Front Pharmacol. 2022;13:950651.","journal-title":"Front Pharmacol"},{"key":"3010_CR90","unstructured":"Gene therapy for Duchenne muscular dystrophy: nearing final tests https:\/\/www.biopharmadive.com\/news\/duchenne-dmd-gene-therapy-sarepta-pfizer\/588272\/.\u00a0Accessed 12 Jul 2024."},{"issue":"6","key":"3010_CR91","first-page":"885","volume":"2","author":"R Wu","year":"2022","unstructured":"Wu R, Song Y, Wu S, Chen Y. Promising therapeutic approaches of utrophin replacing dystrophin in the treatment of Duchenne muscular dystrophy. Fund Res. 2022;2(6):885\u201393.","journal-title":"Fund Res"},{"key":"3010_CR92","doi-asserted-by":"crossref","unstructured":"Andrysiak K, Ferdek PE, Sanetra AM et al. Upregulation of utrophin improves the phenotype of Duchenne muscular dystrophy hiPSC-derived CMs. Mol Ther - Nucleic Acids. 2024;35(3).","DOI":"10.1016\/j.omtn.2024.102247"},{"issue":"1","key":"3010_CR93","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1038\/s41467-020-15971-w","volume":"11","author":"C P\u00e9ladeau","year":"2020","unstructured":"P\u00e9ladeau C, Adam N, Bronicki LM, et al. Identification of therapeutics that target eEF1A2 and upregulate utrophin A translation in dystrophic muscles. Nat Commun. 2020;11(1):1990.","journal-title":"Nat Commun"},{"key":"3010_CR94","unstructured":"Akash MS, Rehman K, Irshad K, Chen S. Pharmaceutical biotechnology in drug development. Elsevier; 2023."},{"key":"3010_CR95","doi-asserted-by":"crossref","unstructured":"Sweetser MT. Chapter 85 - Congenital immunodeficiency. In: Fuhrman BP, Zimmerman JJ, editors. Pediatric critical care (Third Edition). Mosby Philadelphia, 2006. 1320\u20131329.","DOI":"10.1016\/B978-032301808-1.50088-2"},{"key":"3010_CR96","unstructured":"Gene Therapy for Severe Combined Immunodeficiency (SCID) https:\/\/www.news-medical.net\/health\/Gene-Therapy-for-Severe-Combined-Immunodeficiency-(SCID).aspx.\u00a0Accessed 12 Jul 2024."},{"key":"3010_CR97","unstructured":"Role of genes within cells, genetic code, genetic elements that control gene expression https:\/\/nptel.ac.in\/courses\/102103013.\u00a0Accessed 12 Jul 2024."},{"key":"3010_CR98","doi-asserted-by":"crossref","unstructured":"Fischer A, Hacein-Bey-Abina S. Gene therapy for severe combined immunodeficiencies and beyond. J Exp Med. 2019;217(2):e20190607.","DOI":"10.1084\/jem.20190607"},{"issue":"1","key":"3010_CR99","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.gendis.2019.07.007","volume":"7","author":"Z-Y Zhang","year":"2020","unstructured":"Zhang Z-Y, Thrasher AJ, Zhang F. Gene therapy and genome editing for primary immunodeficiency diseases. Genes Dis. 2020;7(1):38\u201351.","journal-title":"Genes Dis"},{"issue":"2","key":"3010_CR100","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.jaci.2020.05.024","volume":"146","author":"CY Kuo","year":"2020","unstructured":"Kuo CY, Kohn DB. Overview of the current status of gene therapy for primary immune deficiencies (PIDs). J Allergy Clin Immunol. 2020;146(2):229\u201333.","journal-title":"J Allergy Clin Immunol"},{"key":"3010_CR101","doi-asserted-by":"crossref","unstructured":"Liu X, Li G, Liu Y, Zhou F, Huang X, Li K. Advances in CRISPR\/Cas gene therapy for inborn errors of immunity.\u00a0Front Immunol. 2023;14:1111777.","DOI":"10.3389\/fimmu.2023.1111777"},{"key":"3010_CR102","doi-asserted-by":"crossref","unstructured":"Olowoyeye A, Okwundu CI. Gene therapy for sickle cell disease. Cochrane Database Syst Rev. 2018;11(11):Cd007652.","DOI":"10.1002\/14651858.CD007652.pub6"},{"issue":"11","key":"3010_CR103","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1182\/blood.2021011488","volume":"138","author":"RJ Jones","year":"2021","unstructured":"Jones RJ, Debaun MR. Leukemia after gene therapy for sickle cell disease: insertional mutagenesis, busulfan, both, or neither. Blood. 2021;138(11):942\u20137.","journal-title":"Blood"},{"key":"3010_CR104","unstructured":"Researchers create new viral vector for improved gene therapy in sickle cell disease https:\/\/www.sciencedaily.com\/releases\/2019\/10\/191002102804.htm.\u00a0Accessed 15 Jul 2024."},{"key":"3010_CR105","doi-asserted-by":"crossref","unstructured":"Vinci P, Di Girolamo FG, Panizon E, Tosoni LM, Cerrato C, Pellicori F, Altamura N, Pirulli A, Zaccari M, Biasinutto C, Roni C. Lipoprotein (a) as a risk factor for cardiovascular diseases: pathophysiology and treatment perspectives. Int J Environ Res Public Health. 2023;20(18):6721.","DOI":"10.3390\/ijerph20186721"},{"issue":"5","key":"3010_CR106","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11883-024-01198-3","volume":"26","author":"M Hoekstra","year":"2024","unstructured":"Hoekstra M, Van Eck M. Gene editing for the treatment of hypercholesterolemia. Curr Atheroscler Rep. 2024;26(5):139\u201346.","journal-title":"Curr Atheroscler Rep"},{"key":"3010_CR107","doi-asserted-by":"publisher","first-page":"100701","DOI":"10.1016\/j.ajpc.2024.100701","volume":"19","author":"M Safarova","year":"2024","unstructured":"Safarova M, Bimal T, Soffer DE, et al. Advances in targeting LDL cholesterol: PCSK9 inhibitors and beyond. Am J Prev Cardiol. 2024;19:100701.","journal-title":"Am J Prev Cardiol"},{"issue":"8","key":"3010_CR108","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1038\/s41587-021-00933-4","volume":"39","author":"T Rothgangl","year":"2021","unstructured":"Rothgangl T, Dennis MK, Lin PJC, et al. In vivo adenine base editing of PCSK9 in macaques reduces LDL cholesterol levels. Nat Biotechnol. 2021;39(8):949\u201357.","journal-title":"Nat Biotechnol"},{"issue":"9","key":"3010_CR109","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1007\/s13238-018-0568-x","volume":"9","author":"L Yang","year":"2018","unstructured":"Yang L, Zhang X, Wang L, et al. Increasing targeting scope of adenosine base editors in mouse and rat embryos through fusion of TadA deaminase with Cas9 variants. Protein Cell. 2018;9(9):814\u20139.","journal-title":"Protein Cell"},{"key":"3010_CR110","doi-asserted-by":"crossref","unstructured":"Hammoudeh S, Gadelhak W, Abdulwahab A, Al-Langawi M, Janahi IA. An Overview of the homozygous cystic fibrosis transmembrane conductance regulator mutation c.3700 A>G (p.Ile1234Val) in Qatar. Curr Genet Med Rep. 2019;7(4):187\u2013190.","DOI":"10.1007\/s40142-019-00174-7"},{"issue":"8","key":"3010_CR111","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1007\/s00424-020-02425-x","volume":"472","author":"DH Shin","year":"2020","unstructured":"Shin DH, Kim M, Kim Y, et al. Bicarbonate permeation through anion channels: its role in health and disease. Pflugers Arch. 2020;472(8):1003\u201318.","journal-title":"Pflugers Arch"},{"key":"3010_CR112","first-page":"100006","volume":"1","author":"ED Chan","year":"2019","unstructured":"Chan ED, Wooten WI, Hsieh EWY, et al. Diagnostic evaluation of bronchiectasis. Respir Med: X. 2019;1:100006.","journal-title":"Respir Med: X"},{"key":"3010_CR113","doi-asserted-by":"crossref","unstructured":"Taccetti G, Francalanci M, Pizzamiglio G et al. Cystic fibrosis: recent insights into inhaled antibiotic treatment and future perspectives. Antibiotics. 2021;10(3).","DOI":"10.3390\/antibiotics10030338"},{"key":"3010_CR114","doi-asserted-by":"publisher","first-page":"107502","DOI":"10.1016\/j.biotechadv.2019.107502","volume":"40","author":"CC Ma","year":"2020","unstructured":"Ma CC, Wang ZL, Xu T, He ZY, Wei YQ. The approved gene therapy drugs worldwide: from 1998 to 2019. Biotechnol Adv. 2020;40:107502.","journal-title":"Biotechnol Adv"},{"issue":"1","key":"3010_CR115","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S2213-2600(19)30337-6","volume":"8","author":"SC Bell","year":"2020","unstructured":"Bell SC, Mall MA, Gutierrez H, et al. The future of cystic fibrosis care: a global perspective. Lancet Respir Med. 2020;8(1):65\u2013124.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3010_CR116","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1038\/s41565-018-0358-x","volume":"14","author":"S Guan","year":"2019","unstructured":"Guan S, Munder A, Hedtfeld S, et al. Self-assembled peptide-poloxamine nanoparticles enable in vitro and in vivo genome restoration for cystic fibrosis. Nat Nanotechnol. 2019;14(3):287\u201397.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"3010_CR117","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41596-022-00755-x","volume":"18","author":"X Wang","year":"2023","unstructured":"Wang X, Liu S, Sun Y, et al. Preparation of selective organ-targeting (SORT) lipid nanoparticles (LNPs) using multiple technical methods for tissue-specific mRNA delivery. Nat Protoc. 2023;18(1):265\u201391.","journal-title":"Nat Protoc"},{"issue":"1","key":"3010_CR118","doi-asserted-by":"publisher","first-page":"3232","DOI":"10.1038\/s41467-020-17029-3","volume":"11","author":"T Wei","year":"2020","unstructured":"Wei T, Cheng Q, Min Y-L, Olson EN, Siegwart DJ. Systemic nanoparticle delivery of CRISPR-Cas9 ribonucleoproteins for effective tissue specific genome editing. Nat Commun. 2020;11(1):3232.","journal-title":"Nat Commun"},{"key":"3010_CR119","doi-asserted-by":"crossref","unstructured":"Yang Q, Zhou Y, Chen J, Huang N, Wang Z, Cheng Y. Gene therapy for drug-resistant glioblastoma via lipid-polymer hybrid nanoparticles combined with focused ultrasound. Int J Nanomed. 2021;16(null):185\u2013199.","DOI":"10.2147\/IJN.S286221"},{"key":"3010_CR120","doi-asserted-by":"crossref","unstructured":"Melamed JR, Yerneni SS, Arral ML, LoPresti ST, Chaudhary N, Sehrawat A, Muramatsu H, Alameh MG, Pardi N, Weissman D, Gittes GK. Ionizable lipid nanoparticles deliver mRNA to pancreatic \u03b2 cells via macrophage-mediated gene transfer. Sci Adv. 2023;9(4):eade1444.","DOI":"10.1126\/sciadv.ade1444"},{"key":"3010_CR121","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/j.actbio.2019.12.015","volume":"103","author":"C Wang","year":"2020","unstructured":"Wang C, Guan W, Peng J, Chen Y, Xu G, Dou H. Gene\/paclitaxel co-delivering nanocarriers prepared by framework-induced self-assembly for the inhibition of highly drug-resistant tumors. Acta Biomater. 2020;103:247\u201358.","journal-title":"Acta Biomater"},{"key":"3010_CR122","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1016\/j.jconrel.2020.01.026","volume":"320","author":"H Zhang","year":"2020","unstructured":"Zhang H, Liu J, Chen Q, Mi P. Ligand-installed anti-VEGF genomic nanocarriers for effective gene therapy of primary and metastatic tumors. J Control Release. 2020;320:314\u201327.","journal-title":"J Control Release"},{"key":"3010_CR123","doi-asserted-by":"publisher","first-page":"120964","DOI":"10.1016\/j.biomaterials.2021.120964","volume":"275","author":"L Cheng","year":"2021","unstructured":"Cheng L, Zhang X, Tang J, Lv Q, Liu J. Gene-engineered exosomes-thermosensitive liposomes hybrid nanovesicles by the blockade of CD47 signal for combined photothermal therapy and cancer immunotherapy. Biomaterials. 2021;275:120964.","journal-title":"Biomaterials"},{"issue":"2","key":"3010_CR124","doi-asserted-by":"publisher","first-page":"714","DOI":"10.1021\/acs.molpharmaceut.0c00461","volume":"18","author":"S Arora","year":"2021","unstructured":"Arora S, Layek B, Singh J. Design and validation of liposomal ApoE2 gene delivery system to evade blood-brain barrier for effective treatment of Alzheimer\u2019s Disease. Mol Pharm. 2021;18(2):714\u201325.","journal-title":"Mol Pharm"},{"key":"3010_CR125","doi-asserted-by":"crossref","unstructured":"Wan T, Zhong J, Pan Q, Zhou T, Ping Y, Liu X. Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases. Sci Adv. 2022;8(37):eabp9435.","DOI":"10.1126\/sciadv.abp9435"},{"key":"3010_CR126","doi-asserted-by":"crossref","unstructured":"Vicente-Pascual M, G\u00f3mez-Aguado I, Rodr\u00edguez-Castej\u00f3n J, Rodr\u00edguez-Gasc\u00f3n A, Muntoni E, Battaglia L, del Pozo-Rodr\u00edguez A, Solin\u00eds Aspiazu M\u00c1. Topical administration of SLN-based gene therapy for the treatment of corneal inflammation by de novo IL-10 production. Pharmaceutics. 2020;12(6):584.","DOI":"10.3390\/pharmaceutics12060584"}],"updated-by":[{"DOI":"10.1208\/s12249-025-03096-6","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,4,3]],"date-time":"2025-04-03T00:00:00Z","timestamp":1743638400000}}],"container-title":["AAPS PharmSciTech"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-03010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1208\/s12249-024-03010-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1208\/s12249-024-03010-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,5]],"date-time":"2025-04-05T22:00:20Z","timestamp":1743890420000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1208\/s12249-024-03010-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,19]]},"references-count":126,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,1]]}},"alternative-id":["3010"],"URL":"https:\/\/doi.org\/10.1208\/s12249-024-03010-6","relation":{"correction":[{"id-type":"doi","id":"10.1208\/s12249-025-03096-6","asserted-by":"object"}]},"ISSN":["1530-9932"],"issn-type":[{"value":"1530-9932","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,19]]},"assertion":[{"value":"30 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 March 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original article has been updated to correct author's name as Thakur Gurjeet Singh. It was incorrectly published as Gurjeet Singh Thakur.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1208\/s12249-025-03096-6","URL":"https:\/\/doi.org\/10.1208\/s12249-025-03096-6","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}],"article-number":"17"}}